Spectrum Pharmaceutical Research Corporation Standardizes on
OmniComm’s TrialMaster EDC Solution
Ft. Lauderdale, Florida – April 20, 2006 - /MarketWire/ - OmniComm Systems, Inc. (OTC Bulletin Board: OMCM), one of the fastest growing companies in the EDC marketplace, announced today that it has entered into a strategic partnership with Spectrum Pharmaceutical Research Corporation, a Contract Research Organization (CRO) located in San Antonio, TX.
The TrialMaster system, the core product of OmniComm Systems, provides Spectrum with a 21 CRF Part 11 compliant
Internet-based data and trial management solution that greatly increases the
efficiency, security and integrity of clinical research data. Founded in 1987,
Spectrum has become a trusted clinical research partner to the pharmaceutical,
biotech, and medical device industries. The most recent collaboration between
OmniComm and Spectrum was initiated by a biopharmaceutical sponsor
selecting the two companies for a planned Phase I study.
Spectrum’s President, Toby Muligan, stated, “Having worked with OmniComm in
the past, we knew they were the perfect match to satisfy our client’s high level
expectations in terms of service, price, and performance. Our client’s trials often
have very complex design requirements that go far beyond standard EDC
implementation. As a CRO, OmniComm’s TrialMaster solution offers us the best
of both worlds in that we can deliver to our clients the functionality they desire at
a price that offers outstanding value.”
OmniComm System’s CEO, Cornelis Wit, further stated, “OmniComm is pleased
that Spectrum is a member of our growing list of CRO Partners. With special
service packaging and pricing, CROs like Spectrum can now deliver trials
deploying our TrialMaster EDC and trial management solution at lower prices
than those run with paper forms. This is a win-win business model for all
parties.”
About OmniComm Systems, Inc.
OmniComm Systems, Inc. is one of the fastest growing
companies in the EDC market place targeting its product TrialMaster to the
pharmaceutical, medical device and biotechnology companies as well as CRO’s.
OmniComm’s growing base of satisfied customers is a direct result of
OmniComm’s employee’s commitment to on-time, quality and within budget
performance.
The TrialMaster system, the core product of OmniComm,
provides trial sponsors with a 21 CRF Part 11 compliant Internet-based data and
trial management solution that greatly increases the efficiency, security and
integrity of clinical research data and thus significantly reduces the time and
expense involved in conducting clinical studies.
Safe Harbor Disclaimer
Statements about OmniComm’s future expectations, including without limitation,
future revenues and earnings, plans and objectives for the future operations,
future agreements, future economic performance, operations and all other
statements in this press release other than historical facts are "forward-looking
statements" within the meaning of Section 27A of the Securities Act of 1933,
Section 21E of the Securities Exchange Act of 1934, and as that term is defined
in the Private Securities Litigation Reform Act of 1995. OmniComm intends that
such forward-looking statements be subject to the Safe Harbors created thereby.
Since these statements involve risks and uncertainties, including but not limited
to economic competitive, governmental, contractual and technological factors
affecting OmniComm’s operations, markets and profitability, actual results could
differ materially and adversely from the expected results.
For more info, please email info@omnicomm.com
Back |
